Cargando…

Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy

BACKGROUND: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initia...

Descripción completa

Detalles Bibliográficos
Autores principales: Lebret, Thierry, Ruffion, Alain, Latorzeff, Igor, Zerbib, Marc, Moreau, Jean-Luc, Rossi, Dominique, Pello-Leprince-Ringuet, Nathalie, Perrot, Valérie, Hennequin, Christophe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295785/
https://www.ncbi.nlm.nih.gov/pubmed/30574196
http://dx.doi.org/10.1177/1756287218808496
_version_ 1783380927304433664
author Lebret, Thierry
Ruffion, Alain
Latorzeff, Igor
Zerbib, Marc
Moreau, Jean-Luc
Rossi, Dominique
Pello-Leprince-Ringuet, Nathalie
Perrot, Valérie
Hennequin, Christophe
author_facet Lebret, Thierry
Ruffion, Alain
Latorzeff, Igor
Zerbib, Marc
Moreau, Jean-Luc
Rossi, Dominique
Pello-Leprince-Ringuet, Nathalie
Perrot, Valérie
Hennequin, Christophe
author_sort Lebret, Thierry
collection PubMed
description BACKGROUND: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initiated hormone therapy with a gonadotropin-releasing hormone (GnRH) analogue then had their treatment regimen modified during the first 24 months. METHODS: A prospective, noninterventional study was carried out in routine clinical practice in France. Patients with locally advanced or metastatic PCa were followed up for 2 years after treatment initiation with a GnRH analogue. The primary endpoint was the proportion of patients with a modification to their initial hormone therapy. RESULTS: In total, 1301 patients were enrolled into the study by 204 physicians, and the primary endpoint could be evaluated for 891 patients. The GnRH analogue treatment was initiated for metastatic PCa (24.2%), locally advanced PCa without planned local treatment (20.6%), locally advanced PCa in association with radiotherapy (31.6%), and biochemical recurrence after local treatment (21.4%). Hormonal treatment was modified in 43.8% (390/891) of patients during the 24-month follow-up period after GnRH analogue initiation. In 61.3% of cases (239/390), the type of modification involved a change of GnRH analogue formulation or switch to another GnRH analogue. A total of five significant predictive factors for GnRH analogue treatment modification were identified: metastatic stage; physician sector; physician speciality; presence or absence of urinary symptoms; and intermittent versus continuous ADT. CONCLUSIONS: This study shows that in 43.8% of the patients with advanced PCa, ADT is modified in the first 2 years after initiation in routine clinical practice. Predictive factors for alteration of ADT were metastatic stage and the choice of an intermittent schedule.
format Online
Article
Text
id pubmed-6295785
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-62957852018-12-20 Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy Lebret, Thierry Ruffion, Alain Latorzeff, Igor Zerbib, Marc Moreau, Jean-Luc Rossi, Dominique Pello-Leprince-Ringuet, Nathalie Perrot, Valérie Hennequin, Christophe Ther Adv Urol Original Research BACKGROUND: No published studies have specifically assessed whether treatment modifications to androgen deprivation therapy (ADT) for prostate cancer (PCa) are frequently carried out in routine clinical practice. The current study was conducted to determine what proportion of patients who had initiated hormone therapy with a gonadotropin-releasing hormone (GnRH) analogue then had their treatment regimen modified during the first 24 months. METHODS: A prospective, noninterventional study was carried out in routine clinical practice in France. Patients with locally advanced or metastatic PCa were followed up for 2 years after treatment initiation with a GnRH analogue. The primary endpoint was the proportion of patients with a modification to their initial hormone therapy. RESULTS: In total, 1301 patients were enrolled into the study by 204 physicians, and the primary endpoint could be evaluated for 891 patients. The GnRH analogue treatment was initiated for metastatic PCa (24.2%), locally advanced PCa without planned local treatment (20.6%), locally advanced PCa in association with radiotherapy (31.6%), and biochemical recurrence after local treatment (21.4%). Hormonal treatment was modified in 43.8% (390/891) of patients during the 24-month follow-up period after GnRH analogue initiation. In 61.3% of cases (239/390), the type of modification involved a change of GnRH analogue formulation or switch to another GnRH analogue. A total of five significant predictive factors for GnRH analogue treatment modification were identified: metastatic stage; physician sector; physician speciality; presence or absence of urinary symptoms; and intermittent versus continuous ADT. CONCLUSIONS: This study shows that in 43.8% of the patients with advanced PCa, ADT is modified in the first 2 years after initiation in routine clinical practice. Predictive factors for alteration of ADT were metastatic stage and the choice of an intermittent schedule. SAGE Publications 2018-10-24 /pmc/articles/PMC6295785/ /pubmed/30574196 http://dx.doi.org/10.1177/1756287218808496 Text en © The Author(s), 2018 http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Lebret, Thierry
Ruffion, Alain
Latorzeff, Igor
Zerbib, Marc
Moreau, Jean-Luc
Rossi, Dominique
Pello-Leprince-Ringuet, Nathalie
Perrot, Valérie
Hennequin, Christophe
Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
title Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
title_full Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
title_fullStr Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
title_full_unstemmed Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
title_short Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
title_sort criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295785/
https://www.ncbi.nlm.nih.gov/pubmed/30574196
http://dx.doi.org/10.1177/1756287218808496
work_keys_str_mv AT lebretthierry criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT ruffionalain criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT latorzeffigor criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT zerbibmarc criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT moreaujeanluc criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT rossidominique criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT pelloleprinceringuetnathalie criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT perrotvalerie criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy
AT hennequinchristophe criteriaforindicationandtreatmentmodificationinacohortofpatientswithprostatecancertreatedwithhormonetherapy